Alnylam and Isis License Intellectual Property for MicroRNA Gene Involved in Hepatitis C Virus Infection; Role of MicroRNA-122 in Hepatitis C Infection Published in Science.

Extract

---

Alnylam and Isis License Intellectual Property for MicroRNA Gene Involved in Hepatitis C Virus Infection; Role of MicroRNA-122 in Hepatitis C Infection Published in Science.

CAMBRIDGE, Mass. & CARLSBAD, Calif. -- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) and Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) announced today a co-exclusive license agreement with Stanford University related to the discovery and development of therapeutic products for hepatitis C virus (HCV) infection by inhibiting a liver-specific microRNA. Data published on September 2, 2005 by Jopling et al. in the journal Science demonstrate that the microRNA known as miR-122 is required for HCV r...

See the full content of this document

---